CSL (OTCMKTS:CSLLY) Shares Gap Down – Here’s Why

CSL Limited Sponsored ADR (OTCMKTS:CSLLY)’s share price gapped down before the market opened on Friday . The stock had previously closed at $56.82, but opened at $53.0960. CSL shares last traded at $53.8025, with a volume of 2,011 shares changing hands.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. Zacks Research upgraded shares of CSL from a “strong sell” rating to a “hold” rating in a report on Monday, December 29th. Royal Bank Of Canada lowered CSL from a “moderate buy” rating to a “hold” rating in a research note on Wednesday. Finally, Canaccord Genuity Group raised CSL from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 28th. One investment analyst has rated the stock with a Strong Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, CSL currently has an average rating of “Moderate Buy”.

CSL Stock Performance

The company has a quick ratio of 1.12, a current ratio of 2.46 and a debt-to-equity ratio of 0.50. The stock has a fifty day moving average of $59.83 and a 200-day moving average of $65.65.

About CSL

CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.

The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.